Study analysis · Journal of geriatric cardiology : JGC · 2026
The safest cholesterol drug for older adults might not be the strongest statin — a new meta-analysis of 43,625 patients ranks moderate-dose pitavastatin #1 for safety.
In older adults, moderate-dose pitavastatin was most likely to be safest, and combining it with ezetimibe lowered LDL the most, but the actual size of benefits wasn't reported.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study combined results from many randomized controlled trials, which are the best type of study for testing if a treatment works. So it can give strong evidence about which cholesterol-lowering drugs are safer or better at lowering cholesterol in older people. However, we only read a short summary, so we can't check all the details.
What’s the bottom line?
This study combined results from 16 randomized trials with over 43,000 older adults to see which cholesterol-lowering drugs work best and are safest. They found that a moderate dose of pitavastatin was likely the safest, ezetimibe was best at preventing death from heart disease, evolocumab was best at preventing death from any cause, and combining pitavastatin with ezetimibe was best at lowering LDL cholesterol. People without existing heart disease seemed to benefit more.
How strong is this study?
The study looked at 16 randomized trials with over 43,000 people, which is a good sign. But we only have the abstract, so we can't see if the trials were done well or if there are problems. That means we should be careful about trusting the results too much until we read the full paper.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=43625)+20/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 535 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. Network meta-analysis of RCTs can establish causation, but relies on assumptions of transitivity and consistency. Abstract only; cannot verify randomization, blinding, allocation concealment, or heterogeneity. Rankings are probabilistic, not definitive.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the study text.
The provided text is only an abstract and does not include a conflict of interest or funding statement, nor author affiliations. Thus, potential conflicts cannot be assessed.
Key takeaways
- 01
The study ranked the drugs: pitavastatin had the highest probability of being safest for side effects; ezetimibe for reducing heart-related deaths; evolocumab for reducing all-cause deaths; and pitavastatin plus ezetimibe for lowering LDL.
- 02
For people without heart disease, the benefits were more pronounced, with significant P-values (0.0059, 0.0096, 0.0100).
- 03
However, the actual number of events prevented or the absolute risk reductions were not reported.
- 04
The study does not provide absolute risks, such as how many people would need to be treated to prevent one death or event.
- 05
It only gives rankings and probabilities.
- 06
So we cannot say, for example, that a certain drug reduces the risk by a specific number of cases per 1,000 people.
- 07
The absolute benefits and harms remain unclear from the abstract.
Practical takeaways
If you're an older adult considering LDL-lowering therapy, ask your clinician about moderate-intensity pitavastatin as a potentially safer option based on this ranking.
Abstract only; no absolute risk or effect sizes reported. Individual decisions should consider full clinical context.
low confidenceFor LDL lowering, discuss combination therapy (pitavastatin + ezetimibe) with your doctor as a potentially more effective strategy than other studied regimens.
Rankings are from network meta-analysis, not head-to-head trials; absolute LDL reductions not reported.
low confidenceIf you don't have existing heart disease, ask whether primary prevention with LDL-lowering may offer greater benefit, as this study found more pronounced effects in non-CVD patients.
Subgroup finding; no absolute risk reduction; not causal proof.
low confidenceWhy this study matters
Safest doesn't mean strongest: pitavastatin tops safety ranking
A network meta-analysis of 16 RCTs (n=43,625) in elderly patients found moderate-intensity pitavastatin had the highest probability of being the safest intervention for adverse events. This challenges the guideline preference for high-intensity statins in high-risk individuals, though absolute risk of side effects was not reported.
Many older adults worry about statin side effects; this suggests a moderate-dose option may be safest.
Different drugs win different outcomes
Ezetimibe had the most favorable safety profile for reducing CVD mortality, while evolocumab was most effective for lowering all-cause mortality. For LDL reduction, the combination of moderate-intensity pitavastatin plus ezetimibe was most effective, followed by moderate-intensity rosuvastatin plus ezetimibe.
There's no single 'best' drug — it depends on whether you prioritize heart death, all-cause death, or LDL lowering.
Primary prevention may get bigger benefit
Subgroup analyses showed significant differences between CVD and non-CVD populations for CVD mortality (P=0.0059), CVD events (P=0.0096), and LDL reduction (P=0.0100), with more pronounced effects in the non-CVD group. This suggests greater efficacy for primary prevention in the elderly.
People without existing heart disease may benefit more from LDL-lowering, raising questions about when to start treatment.
The missing absolute numbers
Despite ranking 16 RCTs and 43,625 patients, the abstract reports no absolute risks or effect sizes. We can't say how many events are prevented per 1,000 people treated, only that one drug ranked highest in probability.
Rankings without absolute numbers can be misleading; patients and doctors need to know the real-world size of benefit and harm.
Combination therapy beats single pills for LDL
The combination of moderate-intensity pitavastatin and ezetimibe was the most effective for LDL reduction, followed by moderate-intensity rosuvastatin plus ezetimibe. This supports combo strategies over simply maxing out a single statin.
For people struggling to lower LDL, adding ezetimibe to a moderate statin may be better than high-dose statin alone.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study combined results from 16 randomized trials with over 43,000 older adults to see which cholesterol-lowering drugs work best and are safest. They found that a moderate dose of pitavastatin was likely the safest, ezetimibe was best at preventing death from heart disease, evolocumab was best at preventing death from any cause, and combining pitavastatin with ezetimibe was best at lowering LDL cholesterol. People without existing heart disease seemed to benefit more.
Research results
The study ranked the drugs: pitavastatin had the highest probability of being safest for side effects; ezetimibe for reducing heart-related deaths; evolocumab for reducing all-cause deaths; and pitavastatin plus ezetimibe for lowering LDL. For people without heart disease, the benefits were more pronounced, with significant P-values (0.0059, 0.0096, 0.0100). However, the actual number of events prevented or the absolute risk reductions were not reported.
What this means - more context
The study does not provide absolute risks, such as how many people would need to be treated to prevent one death or event. It only gives rankings and probabilities. So we cannot say, for example, that a certain drug reduces the risk by a specific number of cases per 1,000 people. The absolute benefits and harms remain unclear from the abstract.
To compare the safety and efficacy of various LDL-lowering strategies in the elderly population.
Network meta-analysis of 16 RCTs (n=43,625) in elderly patients found moderate-intensity pitavastatin had the highest probability of being safest for adverse events, ezetimibe was most favorable for reducing CVD mortality, evolocumab was most effective for all-cause mortality, and the combination of moderate-intensity pitavastatin plus ezetimibe was most effective for LDL reduction. Subgroup analyses showed more pronounced benefits in non-CVD patients (primary prevention) with significant interaction P-values for CVD mortality (P=0.0059), CVD events (P=0.0096), and LDL reduction (P=0.0100). Effect sizes and absolute risks were not reported.
Methods Used
Systematic search of six databases until March 2025; included randomized controlled trials evaluating LDL-lowering agents in elderly; primary outcome was adverse effects; secondary outcomes included composite CVD events, CVD-related mortality, all-cause mortality, and LDL level reduction. Risk of bias assessed with RoB-2. Network meta-analyses performed with subgroup analysis based on underlying CVD using cumulative ranking values.
Main Finding
Moderate-intensity pitavastatin had the highest probability of being the safest intervention for adverse events; ezetimibe demonstrated the most favorable safety profile for reducing CVD mortality; evolocumab was most effective in lowering all-cause mortality; and the combination of moderate-intensity pitavastatin plus ezetimibe was most effective for LDL reduction. Subgroup analyses revealed significant differences between CVD and non-CVD populations in CVD mortality (P=0.0059), CVD events (P=0.0096), and LDL reduction (P=0.0100), with more pronounced effects in the non-CVD group. Absolute risk reductions and effect sizes were not reported.
Confidence Level
Limited - based on abstract only, full methodology not available. The abstract reports low to moderate risk of bias among included trials, but no effect sizes or confidence intervals are provided.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No absolute risk or effect sizes reported in abstract
- •Network meta-analysis rankings based on probabilities, not head-to-head comparisons
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you're an older adult considering LDL-lowering therapy, ask your clinician about moderate-intensity pitavastatin as a potentially safer option based on this ranking.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 535 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Lower probability
on the GRADE evidence scale
This study combined results from many randomized controlled trials, which are the best type of study for testing if a treatment works. So it can give strong evidence about which cholesterol-lowering drugs are safer or better at lowering cholesterol in older people. However, we only read a short summary, so we can't check all the details.
Strengths
- Systematic search of six databases
- Inclusion of only RCTs
- Large total sample size (n=43,625)
Weaknesses
- Full methodology not available - based on abstract only
- Cannot verify randomization, blinding, allocation concealment of included RCTs
- Network meta-analysis assumptions (transitivity, consistency) not detailed
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study combined results from 16 randomized trials with over 43,000 older adults to see which cholesterol-lowering drugs work best and are safest. They found that a moderate dose of pitavastatin was likely the safest, ezetimibe was best at preventing death from heart disease, evolocumab was best at preventing death from any cause, and combining pitavastatin with ezetimibe was best at lowering LDL cholesterol. People without existing heart disease seemed to benefit more.
Research results
The study ranked the drugs: pitavastatin had the highest probability of being safest for side effects; ezetimibe for reducing heart-related deaths; evolocumab for reducing all-cause deaths; and pitavastatin plus ezetimibe for lowering LDL. For people without heart disease, the benefits were more pronounced, with significant P-values (0.0059, 0.0096, 0.0100). However, the actual number of events prevented or the absolute risk reductions were not reported.
What this means - more context
The study does not provide absolute risks, such as how many people would need to be treated to prevent one death or event. It only gives rankings and probabilities. So we cannot say, for example, that a certain drug reduces the risk by a specific number of cases per 1,000 people. The absolute benefits and harms remain unclear from the abstract.
To compare the safety and efficacy of various LDL-lowering strategies in the elderly population.
Network meta-analysis of 16 RCTs (n=43,625) in elderly patients found moderate-intensity pitavastatin had the highest probability of being safest for adverse events, ezetimibe was most favorable for reducing CVD mortality, evolocumab was most effective for all-cause mortality, and the combination of moderate-intensity pitavastatin plus ezetimibe was most effective for LDL reduction. Subgroup analyses showed more pronounced benefits in non-CVD patients (primary prevention) with significant interaction P-values for CVD mortality (P=0.0059), CVD events (P=0.0096), and LDL reduction (P=0.0100). Effect sizes and absolute risks were not reported.
Methods Used
Systematic search of six databases until March 2025; included randomized controlled trials evaluating LDL-lowering agents in elderly; primary outcome was adverse effects; secondary outcomes included composite CVD events, CVD-related mortality, all-cause mortality, and LDL level reduction. Risk of bias assessed with RoB-2. Network meta-analyses performed with subgroup analysis based on underlying CVD using cumulative ranking values.
Main Finding
Moderate-intensity pitavastatin had the highest probability of being the safest intervention for adverse events; ezetimibe demonstrated the most favorable safety profile for reducing CVD mortality; evolocumab was most effective in lowering all-cause mortality; and the combination of moderate-intensity pitavastatin plus ezetimibe was most effective for LDL reduction. Subgroup analyses revealed significant differences between CVD and non-CVD populations in CVD mortality (P=0.0059), CVD events (P=0.0096), and LDL reduction (P=0.0100), with more pronounced effects in the non-CVD group. Absolute risk reductions and effect sizes were not reported.
Confidence Level
Limited - based on abstract only, full methodology not available. The abstract reports low to moderate risk of bias among included trials, but no effect sizes or confidence intervals are provided.
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No absolute risk or effect sizes reported in abstract
- •Network meta-analysis rankings based on probabilities, not head-to-head comparisons
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you're an older adult considering LDL-lowering therapy, ask your clinician about moderate-intensity pitavastatin as a potentially safer option based on this ranking.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 535 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Human Meta-Analysis
Subject
Lower probability
on the GRADE evidence scale
This study combined results from many randomized controlled trials, which are the best type of study for testing if a treatment works. So it can give strong evidence about which cholesterol-lowering drugs are safer or better at lowering cholesterol in older people. However, we only read a short summary, so we can't check all the details.
Strengths
- Systematic search of six databases
- Inclusion of only RCTs
- Large total sample size (n=43,625)
Weaknesses
- Full methodology not available - based on abstract only
- Cannot verify randomization, blinding, allocation concealment of included RCTs
- Network meta-analysis assumptions (transitivity, consistency) not detailed
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study looked at 16 randomized trials with over 43,000 people, which is a good sign. But we only have the abstract, so we can't see if the trials were done well or if there are problems. That means we should be careful about trusting the results too much until we read the full paper.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
25 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=43625)+20/20
- Follow-upno follow-up reported
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 535 / 100
Probability of being correct
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
This design can establish causation. Network meta-analysis of RCTs can establish causation, but relies on assumptions of transitivity and consistency. Abstract only; cannot verify randomization, blinding, allocation concealment, or heterogeneity. Rankings are probabilistic, not definitive.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information provided in the study text.
The provided text is only an abstract and does not include a conflict of interest or funding statement, nor author affiliations. Thus, potential conflicts cannot be assessed.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
9 researchersIf this is your work, this is how we attribute it on Fit Body Science. Karmenia Jessica Kurnia Niaga is listed as the lead author.